Business executive overlooking Japan’s pharmaceutical opportunity, with Mount Fuji, Tokyo skyline, Shinkansen, laboratory scientists, DNA helix, medicine vials, and an upward growth graph.
For too long, if you ask me, the Japan pharmaceutical market opportunity has been treated as […]
Illustration of a company at a crossroads choosing among three market access routes into Japan: Own MAH, 3rd party DMAH, or Japanese partner as MAH, shown as three numbered roads leading toward a Tokyo cityscape.
Entering Japan is not only about regulatory approval, launch planning, and commercial ambition. One of the […]